EichorEICHOR
Location: Milan Synced from ClinicalTrials.gov · August 07, 2026

Clinical studies recruiting near Milan

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
Phase 2 · Research Site · Alexion Pharmaceuticals, Inc. · NCT07157787A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Hav
Phase 3 · Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico · Pfizer · NCT05020236A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migra
Phase 2 · IRCCS Ospedale San Raffaele · AbbVie · NCT06602479Neurosurgical Outcome Network
Phase N/A · Fondazione IRCCS Istituto Neurologico Carlo Besta · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · NCT06724029KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used W
Phase 1/Phase 2 · IRCCS Ospedale San Raffaele ( Site 0171) · Merck Sharp & Dohme LLC · NCT04165070A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Phase 3 · Mangiagalli Clinic IRCCS Ca Granda Foundation Ospedale Maggi · Janssen Research & Development, LLC · NCT06449651Observational Study Protocol: LIVER-R
Phase N/A · Research Site · AstraZeneca · NCT06252753A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Phase 3 · Fondazione IRCCS Istituto Nazionale dei Tumori · Eli Lilly and Company · NCT07218380Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
Phase 3 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT05755386A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Phase 2 · Investigational Site Number : 3800002 · Sanofi · NCT06867094This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide W
Phase 3 · Ospedale San Raffaele · Pfizer · NCT07028853Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease
Phase 3 · Azienda Socio Sanitaria Territoriale Centro Specialistico Or · Amgen · NCT04528082Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Phase 3 · IEO Istituto Europeo di Oncologia · Daiichi Sankyo · NCT07022483Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
Phase 2 · Fondazione Irccs Istituto Dei Tumori Di Milano · Giuseppe Procopio · NCT06302569Monocentric Observational Study on the Diagnostic and Prognostic Role of 18F-PSMA PET (PET/CT and PET/MR) in Prostate Ca
Phase N/A · IRC · IRCCS San Raffaele · NCT06167629Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression
Phase N/A · ASST Fatebenefratelli Sacco · Riccardo Guglielmo · NCT07146503Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
Phase N/A · Gastronterology and Gastrointestinal Endoscopy Unit, IRCCS S · San Raffaele University · NCT06708429A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Phase 3 · Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) · Takeda · NCT06747351Improving Non-invasive Ventilation
Phase N/A · Ospedale San Raffaele di Milano · Università Vita-Salute San Raffaele · NCT01571986Insights From the FAST-TRACK CABG Trial: a Clinical Outcome Study in Patient With Previous Surgical Revascularization fo
Phase N/A · Centro Cardiologico Monzino; IRCCS · Centro Cardiologico Monzino · NCT07628270Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease
Phase 2/Phase 3 · Fondazione IRCCS Istituto Nazionale dei Tumori · Bristol-Myers Squibb · NCT07106762Prospective Multicenter Registry of Gender, Diversity and Inclusion (GEDI) of Women With Acute Coronary Syndrome
Phase N/A · IRCCS San Raffaele Hospital · IRCCS San Raffaele · NCT06441942Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3 · Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Com · Merck Sharp & Dohme LLC · NCT06393374MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · National Cancer Institute (NCI) · NCT05564390A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) G
Phase 1/Phase 2 · National Cancer Institute (NCI) · NCT05099003Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney Injury
Phase 2 · IRCSS San Raffaele · River 2 Renal Corp. · NCT07625553International Prospective REgistry on Pre-pectorAl Breast REconstruction
Phase N/A · Ospedale San Raffaele · IRCCS San Raffaele · NCT05817175Clinical Trial on Bowel Preparation Comparing Mannitol 100g to Plenvu Both in a Same Day Regimen (CLEARWAY)
Phase 3 · Fondazione IRCCS Cà Granda Ospedale Policlinico · NTC srl · NCT07465705This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in
Phase 3 · Ospedale San Raffaele · Pfizer · NCT06758401A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Phase 3 · Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico · Bristol-Myers Squibb · NCT06929273
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.